Venturi Wealth Management LLC Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Venturi Wealth Management LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,175.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 91 shares of the medical research company’s stock after purchasing an additional 87 shares during the quarter. Venturi Wealth Management LLC’s holdings in Bio-Rad Laboratories were worth $30,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Gladius Capital Management LP purchased a new stake in Bio-Rad Laboratories in the 3rd quarter worth about $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories during the fourth quarter worth about $33,000. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $55,000. Finally, Quarry LP boosted its holdings in Bio-Rad Laboratories by 38.1% in the 3rd quarter. Quarry LP now owns 297 shares of the medical research company’s stock worth $99,000 after buying an additional 82 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Price Performance

BIO opened at $277.81 on Wednesday. The stock has a market capitalization of $7.78 billion, a P/E ratio of -4.27 and a beta of 0.90. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The stock has a 50-day moving average price of $330.43 and a 200-day moving average price of $333.76.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.